AstraZeneca has offered about $10 billion for US biotech Pharmaceuticals, which develops drugs against rare forms of obesity. The offer values the shares at $124, while Rhythm's market value is about $6.6 billion. The buyer is willing to pay a premium for its development. For AstraZeneca, this is an expansion of the drug portfolio. The goal is drugs for metabolic disorders and rare diseases, as well as programs for new treatment methods. The high price makes the success of future developments the main condition for reward. It is for future commercial opportunities that AstraZeneca is willing to offer an amount that exceeds the target's current market valuation. This is an offer, not a done deal. The size of the supply shows the high price of specialized biotechnology. For Rhythm, the control of the company becomes the subject of negotiations, and for AstraZeneca, a place in the promising sector of treating serious diseases. ECONOMY